BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30212595)

  • 21. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
    Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
    Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resection strategies for neuroendocrine pancreatic neoplasms.
    Watzka FM; Laumen C; Fottner C; Weber MM; Schad A; Lang H; Musholt TJ
    Langenbecks Arch Surg; 2013 Mar; 398(3):431-40. PubMed ID: 23143147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival.
    Medrano-Guzmán R; López-García SC; Torres-Vargas S; González-Rodríguez D; Alvarado-Cabrero I
    Cir Cir; 2011; 79(6):498-504. PubMed ID: 22169366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Zhang IY; Zhao J; Fernandez-Del Castillo C; Braun Y; Razmdjou S; Warshaw AL; Lillemoe KD; Ferrone CR
    J Gastrointest Surg; 2016 Feb; 20(2):277-83. PubMed ID: 26691146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
    Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
    J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.
    Sallinen VJ; Le Large TYS; Tieftrunk E; Galeev S; Kovalenko Z; Haugvik SP; Antila A; Franklin O; Martinez-Moneo E; Robinson SM; Panzuto F; Regenet N; Muffatti F; Partelli S; Wiese D; Ruszniewski P; Dousset B; Edwin B; Bartsch DK; Sauvanet A; Falconi M; Ceyhan GO; Gaujoux S;
    HPB (Oxford); 2018 Mar; 20(3):251-259. PubMed ID: 28988702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
    Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
    J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic islet cell tumors in adolescents and young adults.
    Waters AM; Maizlin II; Russell RT; Dellinger M; Gow KW; Goldin A; Goldfarb M; Nuchtern JG; Langer M; Vasudevan SA; Doski JJ; Raval M; Beierle EA
    J Pediatr Surg; 2019 Oct; 54(10):2103-2106. PubMed ID: 30954230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database.
    Mao R; Zhao H; Li K; Luo S; Turner M; Cai JQ; Blazer D
    Ann Surg Oncol; 2019 Sep; 26(9):2722-2729. PubMed ID: 31209670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation.
    Chen J; Yang Y; Liu Y; Kan H
    World J Surg Oncol; 2021 Jan; 19(1):11. PubMed ID: 33436017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas.
    Bloomston M; Muscarella P; Shah MH; Frankel WL; Al-Saif O; Martin EW; Ellison EC
    J Gastrointest Surg; 2006 Dec; 10(10):1361-70. PubMed ID: 17175455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases.
    Partelli S; Inama M; Rinke A; Begum N; Valente R; Fendrich V; Tamburrino D; Keck T; Caplin ME; Bartsch D; Thirlwell C; Fusai G; Falconi M
    Neuroendocrinology; 2015; 102(1-2):68-76. PubMed ID: 26043944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
    Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
    Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of pancreatic resection associated with portal vein resection in an Australian tertiary care centre.
    Iorgulescu DG; Ling S; Nikfarjam M; Fink MA; Jones R; Muralidharan V; Starkey G; Christophi C
    ANZ J Surg; 2015 Apr; 85(4):270-3. PubMed ID: 24712309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of portal vein invasion and resection length in pancreatoduodenectomy on the survival rate of pancreatic head cancer.
    Kurihara C; Yoshimi F; Sasaki K; Nakao K; lijima T; Kawasaki H; Nagai H
    Hepatogastroenterology; 2013 Oct; 60(127):1759-65. PubMed ID: 24634947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.
    Cloyd JM; Kopecky KE; Norton JA; Kunz PL; Fisher GA; Visser BC; Dua MM; Park WG; Poultsides GA
    Surgery; 2016 Sep; 160(3):708-13. PubMed ID: 27216830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.
    Wong J; Fulp WJ; Strosberg JR; Kvols LK; Centeno BA; Hodul PJ
    Am J Surg; 2014 Nov; 208(5):775-780. PubMed ID: 24997491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?
    Hodul PJ; Strosberg JR; Kvols LK
    Cancer Control; 2008 Oct; 15(4):314-21. PubMed ID: 18813199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.